P
Protego Bio
Protein stabilizing therapies targeting misfolding diseases
About Protego Bio
Protego Biopharma is a biotechnology startup that is pioneering the discovery and development of innovative therapeutics to treat protein misfolding diseases. The company operates in the pharmaceutical industry, specifically in the drug discovery sector. Its primary focus is on systemic amyloid diseases like light chain (LC) amyloidosis and other monogenetic protein misfolding diseases that cause a variety of health issues including myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases.
Protego Biopharma's business model revolves around the use of advanced bioinformatics, deep biology, and clinical path analysis to identify high-confidence targets for drug development. The company's approach is data-driven and focuses on modifying diseases through an innovative discovery platform. They also use specific and sensitive biomarkers for early patient identification and to measure therapeutic efficacy.
The company's revenue model is likely based on the development and commercialization of its therapeutics. Once a drug is developed, it can be patented and sold to healthcare providers or directly to patients. Additionally, the company may generate income through partnerships or collaborations with other pharmaceutical companies.
The company was co-founded by Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, who have previously demonstrated success in this field with the discovery and development of tafamidis, a drug used for the treatment of transthyretin amyloidosis.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- San Diego, United States
- Employees
- 26
- Open positions
- 3
- Dealroom signal
- 41.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2025 | $130M | $520M | Lightspeed Venture Partners · MPM BioImpact · Digitalis Ventures · Scripps Translational Science Institute | ↗ |
| SERIES AOther financing | Nov 2021 | $51M | $204M | Lightspeed Venture Partners · MPM BioImpact · Vida Ventures | ↗ |
Growth signals
Latest recorded traffic for Protego Bio is 2.1K monthly website visits, down 8.7% over the last three months. Protego Bio's team grew 4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Lightspeed Venture Partners
MPM BioImpact
Vida Ventures
Novartis Venture Fund
Forbion Capital Partners
Digitalis Ventures
Scripps Translational Science Institute
YK Bioventures
Omega Funds
Droia Oncology Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Protego Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Protego Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.